Literature DB >> 12846982

Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease.

Hongmin Wang1, Mika Shimoji, Seong-Woon Yu, Ted M Dawson, Valina L Dawson.   

Abstract

Experimental intoxication models are used to study the more common sporadic form of Parkinson's disease (PD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP) animal models of PD provide a valuable and predictive tool to probe the molecular mechanisms of dopamine neuronal cell death in PD. MPTP is a powerful neurotoxin that induces neuronal degeneration in the substantia nigra pars compacta and produces PD-like symptoms in several mammalian species tested, a feat not yet accomplished in genetically engineered mice expressing human genetic mutations. The mechanisms of MPTP-induced neurotoxicity are not yet fully understood but involve activation of N-methyl-D-aspartate (NMDA) receptors by glutamate, production of NO by nNOS and iNOS, oxidative injury to DNA, and activation of the DNA damage-sensing enzyme poly (ADP-ribose) polymerase (PARP). Recent experiments indicate that translocation of a mitochondrial protein apoptosis inducing factor (AIF) from mitochondria to the nucleus depends on PARP activation and plays an important role in excitotoxicity-induced cell death. This article briefly reviews the experimental findings regarding excitotoxicity, PARP activation, and AIF translocation in MPTP toxicity and dopaminergic neuronal cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846982     DOI: 10.1111/j.1749-6632.2003.tb07471.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  38 in total

Review 1.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

2.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

3.  Activation of the Akt1-CREB pathway promotes RNF146 expression to inhibit PARP1-mediated neuronal death.

Authors:  Hyojung Kim; Jisoo Park; Hojin Kang; Seung Pil Yun; Yun-Song Lee; Yun-Il Lee; Yunjong Lee
Journal:  Sci Signal       Date:  2020-12-22       Impact factor: 8.192

4.  Maternal Omega-3 Supplement Improves Dopaminergic System in Pre- and Postnatal Inflammation-Induced Neurotoxicity in Parkinson's Disease Model.

Authors:  Ana Marcia Delattre; Bruno Carabelli; Marco Aurélio Mori; Paula G Kempe; Luiz E Rizzo de Souza; Silvio M Zanata; Ricardo B Machado; Deborah Suchecki; Belmira L S Andrade da Costa; Marcelo M S Lima; Anete C Ferraz
Journal:  Mol Neurobiol       Date:  2016-02-29       Impact factor: 5.590

Review 5.  NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns.

Authors:  Hassina Massudi; Ross Grant; Gilles J Guillemin; Nady Braidy
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

Review 6.  Environmental toxins and alpha-synuclein in Parkinson's disease.

Authors:  Yanying Liu; Hui Yang
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

7.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

Review 8.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

9.  Vitamin A depletion causes oxidative stress, mitochondrial dysfunction, and PARP-1-dependent energy deprivation.

Authors:  Haw-Jyh Chiu; Donald A Fischman; Ulrich Hammerling
Journal:  FASEB J       Date:  2008-08-01       Impact factor: 5.191

Review 10.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.